NCT03976362 2026-02-25
KEYLYNK-008
Merck Sharp & Dohme LLC
Phase 3 Completed
Clinical Trials
8 trialsNCT05261399 2025-01-10
SAFFRON
AstraZeneca
Phase 3 Recruiting
NCT01706939 2024-08-29
The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer
Icahn School of Medicine at Mount Sinai
Phase 3 Active not recruiting
NCT03952403 2023-08-08
A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Shanghai Henlius Biotech
Phase 3 Unknown
NCT04033354 2023-08-08
A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC
Shanghai Henlius Biotech
Phase 3 Unknown
NCT02367781 2021-08-09
IMpower130
Hoffmann-La Roche
Phase 3 Completed
NCT00003558 2013-08-07
Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00193596 2013-05-03
Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site
SCRI Development Innovations, LLC
Phase 3 Completed